IL190842A0 - Use of sdf-1 for the treatment and/or prevention of neurological diseases - Google Patents
Use of sdf-1 for the treatment and/or prevention of neurological diseasesInfo
- Publication number
- IL190842A0 IL190842A0 IL190842A IL19084208A IL190842A0 IL 190842 A0 IL190842 A0 IL 190842A0 IL 190842 A IL190842 A IL 190842A IL 19084208 A IL19084208 A IL 19084208A IL 190842 A0 IL190842 A0 IL 190842A0
- Authority
- IL
- Israel
- Prior art keywords
- sdf
- prevention
- treatment
- neurological diseases
- neurological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05110206 | 2005-10-31 | ||
US73414205P | 2005-11-07 | 2005-11-07 | |
PCT/EP2006/067949 WO2007051785A2 (en) | 2005-10-31 | 2006-10-30 | Use of sdf-1 for the treatment and/or prevention of neurological diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IL190842A0 true IL190842A0 (en) | 2008-11-03 |
Family
ID=38006228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL190842A IL190842A0 (en) | 2005-10-31 | 2008-04-14 | Use of sdf-1 for the treatment and/or prevention of neurological diseases |
Country Status (2)
Country | Link |
---|---|
EC (1) | ECSP088411A (en) |
IL (1) | IL190842A0 (en) |
-
2008
- 2008-04-14 IL IL190842A patent/IL190842A0/en unknown
- 2008-04-29 EC EC2008008411A patent/ECSP088411A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP088411A (en) | 2008-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200800981B (en) | Use of SDF-1 for the treatment and/or prevention of neurological diseases | |
ZA200703601B (en) | Medicaments for the treatment or prevention of fibriotic diseases | |
ZA200804646B (en) | The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases | |
EP1809369A4 (en) | Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto | |
EP1814909A4 (en) | Use of aimp2dx2 for the diagnosis and treatment of cancer | |
EP1968607A4 (en) | Treatment of cancer and other diseases | |
GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
EP1711197A4 (en) | Methods and compositions for the prevention and treatment of inflammatory diseases or conditions | |
IL184124A0 (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
EP1680145A4 (en) | Methods and compositions for the treatment of neurological disease | |
IL187405A0 (en) | Methods and compositions for the treatment of pain | |
EP1740221A4 (en) | Methods and compositions for the treatment of polycystic diseases | |
SI1812797T1 (en) | Compositions and methods for the treatment and prevention of hyperproliferative diseases | |
ZA200707955B (en) | Methods and pharmaceutical compositions for the treatment of neurological damage | |
EP1781318A4 (en) | Methods and compositions for the treatment of polycystic diseases | |
HK1101674A1 (en) | Composition for the prevention and treatment of allergic inflammatory disease | |
GB0523964D0 (en) | The treatment of ophthalmic diseases | |
IL190842A0 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
EP1807108A4 (en) | Methods for the treatment and prevention of diseases of biological conduits | |
ZA200710476B (en) | Methods and compositions for the treatment of pain | |
GB0419828D0 (en) | The treatment of inflammatroy disorders and pain | |
GB0513413D0 (en) | The treatment of inflammatory disorders and pain | |
GB0502596D0 (en) | The treatment of inflammatory disorders and pain | |
IL188056A0 (en) | Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases | |
EP1890693A4 (en) | Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases |